

**Oklahoma Health Care Authority
Drug Utilization Review Board**
(DUR Board)
Meeting – November 10, 2010 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

- 1. Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

- 2. Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. October 13, 2010 DUR Minutes – Vote
 - B. October 14, 2010 DUR Recommendation Memorandum
 - C. Correspondence

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

- 4. Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review for September 2010
 - B. Retrospective Drug Utilization Review Response for July 2010
 - C. Medication Coverage Activity Audit for October 2010
 - D. Pharmacy Help Desk Activity Audit for October 2010

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

- 5. Action Item – Vote on 2011 Meeting Dates – See Appendix C.**

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman:

- 6. Action Item – Vote to Change Criteria for Growth Hormone Product Based Prior Authorization Category – See Appendix D.**
 - A. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

- 7. Action Item – Vote to Prior Authorize Butrans™, Primlev™, Xolox®, Exalgo™ ER, Rybix™ ODT, and Suboxone®/Subutex® – See Appendix E.**
 - A. COP Recommendations

Items to be presented by Dr. Patel, Dr. Muchmore, Chairman

8. **Action Item – Vote to Prior Authorize Vimovo™ – See Appendix F.**
 - A. Product Summary
 - B. COP Recommendations

Items to be presented by Dr. Robinson, Dr. Muchmore, Chairman

9. **Action Item – Annual Review of Ocular Allergy Product Based Prior Authorization Category and Vote to Prior Authorize Bepreve™ and Lastacraft™ – See Appendix G.**
 - A. Current Authorization Criteria for Ocular Allergy Products
 - B. Utilization Review
 - C. COP Recommendations
 - D. Product Details

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

10. **30 Day Notice to Prior Authorize Metozolv® ODT – See Appendix H.**
 - A. Product Summary
 - B. COP Recommendations
 - C. Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

11. **30 Day Notice to Prior Authorize Special Formulations and Application of Age Restriction of Alzheimer's Medications – See Appendix I.**
 - A. Overview
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Chonlahan, Dr. Muchmore, Chairman

12. **Utilization Review of Benign Prostate Hyperplasia (BPH) Medications – See Appendix J.**
 - A. Overview
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

13. **FDA and DEA Updates – See Appendix K.**

14. **Future Business**
 - A. Annual Review of Antihypertensives
 - B. Utilization Review Antipsychotics
 - C. Annual Review Advair® / Symbicort®
 - D. New Product Reviews

15. **Adjournment**